Tanios Bekaii‐Saab

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Germline Cancer Testing in Unselected Patients With Neuroendocrine Neoplasms: A Multi-center Prospective Study

  Pancreas · 2026-06-04

• Bespoke Circulating Tumor DNA Testing for Diagnostic Resolution, Disease Surveillance, and Treatment Monitoring in Hepatopancreatobiliary Malignancies: A Real-World Experience

  JCO Precision Oncology · 2026-04-01

• Single-arm phase 2 study of the FGFR inhibitor futibatinib (Futi) in combination with pembrolizumab (Pem) in patients with FGF19 expressing advanced or metastatic hepatocellular carcinoma (aHCC).

  Journal of Clinical Oncology · 2026-01-10

• A phase II randomized study of atezolizumab plus multikinase inhibitor (MKI) versus MKI alone in patients with advanced hepatocellular carcinoma previously treated with atezolizumab plus bevacizumab (Atezo/Bev).

  Journal of Clinical Oncology · 2026-01-10

• Evaluating Food and Drug Administration approved gastrointestinal cancer drugs: clinical benefit and trial endpoints over the past two decades

  The Oncologist · 2025-12-01 · 1 citations

• Optimized dose schedule of rucaparib and liposomal irinotecan/5‐fluorouracil in metastatic gastrointestinal cancers: A phase 1 study

  Cancer · 2025-11-22 · 1 citations

• Cognitive bias in LLM reasoning compromises interpretation of clinical oncology notesPreprint

  ArXiv.org · 2025-11-16

• Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers

  Liver International · 2025-11-12 · 6 citations

• Optimized Dosing of Regorafenib in Patients With Metastatic Colorectal Cancer: A Practical Guide for Oncologists, Advanced Practice Providers, and Pharmacists

  Journal of the Advanced Practitioner in Oncology · 2025-11-10

• 444 Impact of homologous recombination deficiency on response to chemoimmunotherapy in biliary tract cancer

  Regular and Young Investigator Award Abstracts · 2025-11-01

• 541 ctDNA as a potential surrogate biomarker for response to combination vilastobart and atezolizumab in heavily pretreated microsatellite stable (MSS) metastatic colorectal cancer (mCRC) (NCT04896697)

  Regular and Young Investigator Award Abstracts · 2025-11-01

• Immune Checkpoint Inhibitors for Mismatch Repair–Deficient Gastroesophageal Adenocarcinoma: Outcomes and Feasibility of Nonoperative Management at Mayo Clinic

  JCO Precision Oncology · 2025-11-01 · 3 citations

• Evaluating third-line therapies in refractory metastatic colorectal cancer: a systematic review and network meta-analysis

  Digestive and Liver Disease · 2025-10-28 · 1 citations

• Targeted Therapy Improves Real-World Survival in Patients with Molecularly Matched Advanced Biliary Tract CancerPreprint

  Research Square · 2025-10-12

• Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab

  European Journal of Cancer · 2025-10-04 · 1 citations

• First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study

  The Oncologist · 2025-09-18 · 3 citations

• Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study

  The Oncologist · 2025-09-16

• Exploratory Analysis of PET and CA 19-9 Response in Pancreatic Ductal Adenocarcinoma Outcomes: A Secondary Analysis of a Prospective Phase 2 Trial

  International Journal of Radiation Oncology*Biology*Physics · 2025-09-01

• Midyear highlights in gastrointestinal cancers: expert perspectives.

  PubMed · 2025-09-01

• Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial

  ESMO Open · 2025-08-01 · 3 citations